Aligos Therapeutics (ALGS) Net Cash Flow (2019 - 2026)

Aligos Therapeutics (ALGS) has reported Net Cash Flow for 8 consecutive years, with $269000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow rose 100.49% year-over-year to $269000.0; the trailing twelve-month figure through Jun 2026 stood at $11.7 million (up 144.17% YoY), and the FY2025 full-year result was -$18.7 million, up 81.05% from the prior year.
• Net Cash Flow retreated to $269000.0 in Q2 2026 per ALGS's latest filing, from $11.7 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $65.3 million in Q4 2023 and bottomed at -$111.4 million in Q1 2024.
• Historically, Net Cash Flow has averaged -$8.7 million across 5 years, with a median of -$1.1 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Net Cash Flow surged 1390.45% in 2023, then plunged 4551.65% in 2024.
• Over 5 years, Net Cash Flow stood at -$5.1 million in 2022, then soared by 1390.45% to $65.3 million in 2023, then tumbled by 97.45% to $1.7 million in 2024, then tumbled by 1519.15% to -$23.6 million in 2025, then jumped by 101.14% to $269000.0 in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $269000.0, $11.7 million, and -$23.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.